Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
August 16, 2021 19:55 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LONDON , Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the London-based Great Ormond Street Hospital...
TLX66 Meets Study Objectives in Patients with AL Amyloidosis
May 24, 2021 20:59 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and SOUTHAMPTON, United Kingdom, May 25, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company’s bone marrow...
Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine
November 29, 2020 21:07 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and BAAR, Switzerland, Nov. 29, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into an agreement with Scintec...